Long non-coding RNAs and transposable elements: A functional relationship

Stem Cells International

Feng

et al. 2021

Pluripotency and self-renewal of embryonic stem cells (ESCs) are marked by core transcription regulators such as Oct4, Sox2, and Nanog. Another important marker of pluripotency is the long noncoding RNA (lncRNA). Here, we ind that a novel long noncoding RNA (lncRNA) Lx8-SINE B2 is a marker of pluripotency. LncRNA Lx8-SINE B2 is enriched in ESCs and downregulated during ESC differentiation. By rapid amplification of cDNA ends, we identified the full-length sequence of lncRNA Lx8-SINE B2. We further showed that transposable elements at upstream of lncRNA Lx8-SINE B2 could drive the expression of lncRNA Lx8-SINE B2. Furthermore, ESC-specific expression of lncRNA Lx8-SINE B2 was driven by Oct4 and Sox2. In summary, we identified a novel marker lncRNA of ESCs, which is driven by core pluripotency regulators.

Section: Discussionmentioning

confidence: 99%

Discovery of a Novel Long Noncoding RNA Lx8-SINE B2 as a Marker of Pluripotency

Chen

Stem Cells International

Feng

et al. 2021

“…As for lncR-NAs, there are no feasible or experimental therapies that directly target lncRNAs as yet due to their low expression and the lack of effective tools for adaptation to their particular features. 175,176 With respect to circRNAs, precise mechanisms related to cancer initiation and progression other than miRNA sponges remain to be elucidated, and more controlled and large-scale clinical studies are needed before cancer-specific circRNAs can be applied in clinical practice. That being said, on the other hand, tremendous progress has been made in terms of therapeutics targeting miRNAs, especially in the treatment of various solid tumour types using nanoparticle-conjugated miRNA mimetics.…”

Section: Targeting Ncrnasmentioning

confidence: 99%

Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells

Gong

et al. 2020

Cell Proliferation

“…Long noncoding RNAs (lncRNAs) are a group of noncoding RNAs to be defined as more than 200 bp in length with no protein-coding function [ 3 ]. LncRNAs were first discovered in 2002 in mice lacking of specific and complete open reading frames.…”

Section: Introductionmentioning

confidence: 99%

Long Noncoding RNA RP11-357H14.17 Plays an Oncogene Role in Gastric Cancer by Activating ATF2 Signaling and Enhancing Treg Cells

Tang

Wang

BioMed Research International

et al. 2021

Background. Gastric cancer (GC) is one of the most common malignant tumors in the world. The potential functions and mechanisms of long noncoding RNAs (lncRNAs) in GC development are still unclear. It is of great significance to explore the prognostic value of LncRNA signatures for GC. Methods. LncRNAs differently expressed in GC and their prognostic value were studied based on The Cancer Genome Atlas (TCGA) database. The functional regulatory network and immune infiltration of RP11-357H14.17 were further studied using a variety of bioinformatics tools and databases. Results. We found that the high expression of RP11-357H14.17 was closely associated with shortened overall survival (OS) and poor prognosis in gastric cancer patients. We also found that its expression was related to clinical features including tumor volume, metastasis, and differentiation. Functional enrichment analysis revealed that RP11-357H14.17 is closely related to enhanced DNA replication and metabolism; ssGSEA analysis implied the oncogenic roles of RP11-357H14.17 was related to ATF2 signaling and Treg cell differentiation. Furthermore, we verified such link by using real-time PCR and IHC staining in human GC samples. Conclusion. We demonstrate that RP11-357H14.17 may play a crucial role in the occurrence, development, and malignant biological behavior of gastric cancer as a potential prognostic marker for gastric cancer.